Leap Therapeutics, Inc.
LPTXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DKN-01 | Phase 2 | Colorectal Cancer | - | - |
300mg DKN-01 | Phase 2 | Endometrial Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Leap Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Leap Therapeutics, Inc.'s (LPTX) pipeline across Phase 2. Its lead program is DKN-01 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Leap Therapeutics, Inc.'s next FDA catalyst?→
Leap Therapeutics, Inc.'s (LPTX) next tracked catalyst is a Phase 2 expected January 31, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LPTX biotech catalysts?→
Add LPTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Leap Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.